I have said in the past that people should not approach it as a EPT vs RAP battle , both companies are not competitors they co exist in a emerging industry of medical phone apps.
I hope both do extemely well and certainly I think the market cap of plus $300M for RAP which is yet to have a commercial product until at least next year bodes as a potential beacon to the market about how successful EPT can be.
The success of each is great for all holders
But in comparison I do believe that commercial product timelines stated by both companies is next year which is about the same , EPT will have the development of the kids app to roll out later on as well which I think will be huge add on
Then a key criteria for me is management , as I said before nothing against the RAP management but when you compare CVs , EPT clearly have the guys who have done this biotech commercialisation before for Cochlear and Resmed, so I weight more confidence in EPT management to get it done, but I hope both managements can deliver
MNQ Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
HotCopper & The Market Online will be live From the Floor at the Mining News Select Conference and we want to bring the voice of our online audience to the show with us.